Transcatheter techniques using coils and vascular plugs for peripheral artery and vein embolization continue to increase in popularity, offering alternatives to surgical procedures that can lead to shorter hospital stays and reduced health care costs. The IMPEDE Embolization Plug product family (Shape Memory Medical) represents the latest advancement in embolotherapy using a novel, biodegradable shape memory polymer (SMP).

SMPs belong to a decades-old, broad class of synthetic materials that can be designed to change one or more of their properties (in this case their shape) upon stimulation by external triggers. SMPs were first investigated in the 1960s and more aggressively developed in the 1980s, at the same time that researchers were investigating vascular stents made of the shape memory alloy nitinol. However, unlike nitinol, which is actuated by heat, stress, and strain, SMPs collectively have a broader range of both physical (eg, heat, light, electric or magnetic fields) and chemical (eg, pH, biological stimuli) triggers, a greater opportunity for multiple and/or reversible responses, a better tolerance of strain with higher elastic deformation, and lower density than the shape memory alloys. SMPs have been studied for their utility as medical devices for multiple clinical applications, some of which are biodegradable, adding to their versatility.

A NEW AGE OF PERIPHERAL EMBOLIZATION THERAPY: DEVELOPMENT OF PROPRIETARY SMPs

Among the many polymers from which SMPs can be constructed, polyurethanes are particularly well suited for biomedical applications. Nontoxic, these porous structures can be chemically manipulated and programmed to respond to a variety of stimuli. In the early 2000s, researchers at Lawrence Livermore National Laboratory (LLNL) began work on refining a polyurethane-based SMP developed for neurovascular occlusion. Funded by grants from the National Institute of Biomedical Imaging and Bioengineering (a division of the National Institutes of Health), the LLNL researchers transitioned the work to Texas A&M University to develop tunable, thermoset SMPs that changed from a set shape to a “memorized” configuration upon an increase in temperature and exposure to a liquid environment (eg, blood). The goal was to develop catheter-based medical devices that utilized the shape-shifting characteristics of SMPs to rapidly occlude blood flow.

In the laboratory, the researchers tuned SMP formulations and pore sizes (Figure 1) to create materials with differing cross-link densities, glass transition temperatures (threshold for retaining the primary expanded state), and moisture plasticization and expansion rates. To test...
a promising formulation, the SMP was chemically created in its primary expanded shape, and then small holes were made in the pore membranes to maximize blood flow through the structure and promote clotting and subsequent connective tissue deposition.\textsuperscript{15,16} The SMP was crimped into the desired secondary shape (eg, for catheter delivery) above its glass transition temperature and cooled; only when the SMP again experienced conditions above its transition temperature would it recover its primary expanded shape. Tuning the SMP formulation and pore size altered the working time during catheter delivery before the material begins to expand.

Experimental studies on the SMP in various embolic applications proved that the material could be compressed to a size compatible with catheter delivery and then passively actuated within a vessel, achieving up to a 100-fold volume expansion, a large surface-to-volume ratio, and a tortuous flow path.\textsuperscript{17-20} In 2009, the researchers formed Shape Memory Medical Inc. to study and market vascular occlusion devices constructed with this proprietary SMP technology.

THE PRINCIPLES OF SMP FOR EMBOLOTHERAPY

SMP is crimped into a secondary shape for low-profile catheter delivery (Figure 2). In its expanded shape, Shape Memory Medical’s proprietary SMP offers several unique advantages in vessel embolization, all of which are based on four principles: (1) predictable space filling, (2) stable clot formation, (3) progressive healing, and (4) imaging clarity.

The first principle of the SMP is predictable space filling, as the size, shape, and morphology are consistent throughout the device. Studies have shown that the high-volume embolic material can predictably and effectively fill a void with low radial force.\textsuperscript{19,21} The material is highly compliant and exerts minimal force on anatomic boundaries,\textsuperscript{22} which translates to low vessel or target lesion trauma.

The second principle of the SMP is stable clot formation through the porous embolic scaffold. The inherent 100% packing volume of the porous embolic scaffold slows blood flow and induces rapid thrombus formation throughout its structure,\textsuperscript{16,20,23} a factor that Yasumoto et al showed was important in avoiding recanalization.\textsuperscript{24} As blood flows through the porous, high-surface-area material, thrombus forms within the pores due to blood flow stasis, and with reduced turbulence, these clots become stable quickly. This is the intended effect of any embolization procedure (Figure 3).

The third principle of the SMP is enhanced healing. Investigations have found that stable clot formation leads to enhanced intradevice healing, evidenced by connective tissue deposition that slowly and gradually replaces the biodegradable SMP.\textsuperscript{20,25} In a microscopic assessment of the healing process of an IMPEDE Embolization Plug in a porcine model, Jessen et al described the cellular-level mechanisms of the SMP through 90 days postimplantation compared to controls (a nitinol vascular plug and nylon-fibered platinum embolization coils).\textsuperscript{20} The authors observed that the...
SMP plug implantation initiated an acute inflammatory response, in combination with the clotting cascade, to form an initial thrombus throughout the porous embolic scaffold. Over 90 days, there was progressive intra-aneurysm healing, with gradual, noninflammatory replacement of SMP struts with collagenous connective tissue. Importantly, this series of cellular processes resulted in a stable vessel occlusion, with no microscopic indication of a sustained chronic-active inflammatory response (Figure 4).

The last principle of the SMP is imaging clarity. Because SMP is radiolucent, surrounding anatomy is more visible during procedural and follow-up imaging (Figure 5). The material is visible under ultrasound to appreciate its expansion and filling capabilities.

**IMPEDE EMBOLIZATION PLUG PRODUCT FAMILY**

The IMPEDE Embolization Plug product family is designed to obstruct or reduce the rate of blood flow in the peripheral vasculature. Both the IMPEDE and IMPEDE-FX Embolization Plugs are CE Marked for use in the European Union and other countries that recognize CE Marking and cleared for use in the United States. The SMP component of the device is crimped for catheter delivery, and once implanted at the target site, the SMP expands to its memorized shape, stagnating blood flow for stable clot formation and gradual conversion to mature, connective tissue. The IMPEDE Embolization Plug contains a nitinol anchor coil, which stabilizes the device in higher-flow situations; the IMPEDE-FX Embolization Plug is identical to the IMPEDE Embolization Plug but without an anchor coil (Figure 6). Both devices provide an approximate 1.25-mL volume embolic material fill capacity and are designed with a proximal platinum/iridium marker band for visualization under fluoroscopy because the SMP is radiolucent. The IMPEDE Embolization Plug, which comes in three sizes to embolize vessels from 2 to 10 mm in diameter, may be used in combination with the IMPEDE-FX Embolization Plug (6- to 12-mm vessel diameters) to maximize embolic material space filling. Notably, an IMPEDE...
Embolic Plug leaves behind less material than traditional embolization devices since the SMP biodegrades. In 2019, the IMPEDE Embolization Plug received awards for innovation* and commercialization success.**

**CLINICAL APPLICATIONS AND TRIALS**

The IMPEDE and IMPEDE-FX Embolization Plugs have been used to treat a wide range of conditions, including vascular malformations, arteriovenous fistulas, pelvic congestion syndrome, hemorrhage, tumors, aneurysms, endovascular aneurysm repair (EVAR) endoleaks, and aortic dissection.

To date, nearly 600 patients have been successfully treated worldwide with the IMPEDE and IMPEDE-FX Embolization Plugs. In New Zealand, the EMBO-FX prospective safety study of the IMPEDE and IMPEDE-FX Embolization Plugs (EMBO-PMS UK; NCT04044443) is evaluating the safety and efficacy of these devices. Case examples are shown in Figures 7-9, and early results were published in 2021.***

**SUMMARY**

Studies have shown that the SMP-based IMPEDE Embolization Plug product family offers predictable, controlled, high-volume fill, encouraging stasis and rapid thrombus formation with progressive healing as the biodegradable SMP is replaced by mature connective tissue over time. The SMP plugs are compliant, exerting minimal force on the target vessel or lesion and are radiolucent, facilitating imaging of surrounding anatomy.

---

**REFERENCES**

The IMPEDE and IMPEDE-FX Embolization Plugs are indicated for use to obstruct or reduce the rate of blood flow in the peripheral vasculature. In the United States, the IMPEDE Embolization Plug is indicated to obstruct or reduce the rate of blood flow in the peripheral vasculature, and the IMPEDE-FX Embolization Plug is indicated for use with the IMPEDE Embolization Plug to obstruct or reduce the rate of blood flow in the peripheral vasculature. Refer to the instructions for use, supplied with each device, for a complete statement of the indications, contraindications, warnings, and instructions for use. For more information, visit www.shapemem.com.